2026-04-14T05:46:57Zhttps://recercat.cat/oai/requestoai:recercat.cat:2445/2228392026-03-05T19:09:16Zcom_2072_1057col_2072_478858col_2072_478916col_2072_478917
RECERCAT
author
Giralt, Marina
author
Ferrer, Roser
author
Díaz Troyano, Noelia
author
Vega, Belén
author
Luque Ramírez, Manuel
author
Martínez, Sílvia
author
Fernández, Bárbara
author
Martínez Serrano, Irene
author
Fabregat, Aleix
author
Urgell, Eulàlia
author
Cardona, Ignasi
author
Casals, Gregori
author
Escobar Morreale, Héctor F.
2025-08-29T11:28:50Z2025-08-29T11:28:50Z2025-03-212025-08-26T10:01:23Z
Background: Exemestane, an aromatase inhibitor commonly used for breast cancer treat- ment, shares structural similarities with sex steroids analyzed in clinical laboratories. We aimed to investigate the influence of exemestane cross-reactivity in the measurement of sex steroids across various immunoassays. Methods: We conducted a multicenter study involving measurements of androstenedione, testosterone, estradiol, progesterone , 17-hydroxyprogesterone in serum samples from women undergoing exemestane therapy (N =15; 25 mg/day). Measurements were per- formed using liquid chromatography-mass spectrometry (LC-MS) , various commercially available chemiluminescence immunoassays, ELISA, and radioimmunoassay. In-vitro cross-reactivity was assessed by adding exemestane and 17-hydroexemestane to serum samples. Results: Patients undergoing exemestane therapy had markedly falsely elevated andro- stenedione results in all immunoassays evaluated (N = 4), which correlated with serum ex- emestane levels. In-vitro experiments confirmed this interference to be caused by cross-re- activity with exemestane. Additionally, one immunoassay yielded falsely elevated estradiol results in 20% of patients. However, in-vitro experiments did not confirm this to be caused by cross-reactivity with exemestane or 17-hydroexemestane. Conclusions: Exemestane cross-reacts with androstenedione immunoassays, causing falsely elevated results in treated patients. This analytical interference may raise unneces- sary concerns, leading to expensive diagnostic workups.
cc by-nc-nd (c) Giralt, Marina et al, 2025 http://creativecommons.org/licenses/by-nc-nd/3.0/es/ info:eu-repo/semantics/openAccess
Farmacovigilància
Radioimmunoassaig
Drug monitoring
Radioimmunoassay
Analytical Interference of Exemestane With Androstenedione Immunoassays
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion